ASCO 2020 Preview: A panel discussion of clinical presentations with practice changing potential

About Kantar

Kantar is the world’s leading evidence-based insights and consulting company. We have a complete, unique and rounded understanding of how people think, feel and act; globally and locally in over 90 markets. By combining the deep expertise of our people, our data resources and benchmarks, our innovative analytics and technology, we help our clients understand people and inspire growth.

Kantar’s health division provides specialized data and consulting to support commercial and clinical business decisions. We work with the world's leading pharmaceutical and biotech companies before during and after launch to improve patient outcomes. For more information please visit https://www.kantar.com/expertise/health.

ASCO 2020 Preview: A panel discussion of clinical presentations with practice changing potential

ASCO is taking a new format this year, but our coverage is not. The ASCO 2020 preview brings together experts from clinical, commercial, and financial sectors to discuss which agents have the most potential to have a near-term impact on treatment practices across a number of oncology indications.

Topics include:
Bladder cancer
Gastrointestinal cancers
Hodgkin Lymphoma
Multiple myeloma
NSCLC
Noteworthy new therapies in early-stage development

Date Recorded: Thursday 28th, May 2020 at 12PM ET

Watch Archive

Panelists:


 Stephanie Hawthorne, Ph.D
Stephanie Hawthorne, Ph.D
Vice President, Health Division
Kantar
 Brad Loncar
Brad Loncar
Investor, CEO
Loncar Investments
 Lee S. Schwartzberg, M.D., F.A.C.P.
Lee S. Schwartzberg, M.D., F.A.C.P.
Chief, Division of Hematology Oncology
The University of Tennessee Health Science Center
Chief Medical Officer, OneOncology

Moderated By:


Don Sharpe
Don Sharpe
President
OBR
A free one hour webinar brought to you by Kantar.